QT Imaging Holdings Announces Further Expansion of Locations Offering Its Technology at Vitality Renewal, in Illinois

NOVATO, Calif.--(BUSINESS WIRE)--QT Imaging Holdings, Inc. (NASDAQ:QTI) a medical device company engaged in research, development, and commercialization of innovative body imaging systems, is pleased to announce further expansion of locations offering the Breast Acoustic CT™ Scanner to Vitality Renewal Functional Medicine, in Crystal Lake, Illinois. The commercial shipment was made together with our strategic business and distribution partner.

Dr. Yvonne Karney, founder of Vitality Renewal Functional Medicine, has been an obstetrics and gynecology doctor for 25 years. Dr. Karney served in the Air Force for 8 years.

“I cannot be more excited that QTI’s Breast Acoustic CT Scanner™ will be available in Chicagoland this summer! The QTscan™ is the first non-invasive breast imaging technology that provides a true 3D image of the breast’s microanatomy down to a few hundred cells without compression or harmful radiation. FDA cleared, and more accurate than mammography and hand-held ultrasound at identifying certain breast structures, the QTscan™ algorithm can systematically strip away normal tissues to expose an underlying mass deep within the dense breast tissue,” said Dr. Karney. “The goal of mammography is to detect cancer early, making treatment easier and resulting in a lower death rate from breast cancer, but there are a few substantial limitations of this imaging modality, which has been the standard of care for decades. Not all breast cancers have calcifications, and these are missed with mammography¹. For women with dense breasts, meaning a higher ratio of fibrous to fat tissue, the mammogram is difficult to interpret. This is a significant limitation, because over 40% of women have dense breasts.² Half of women screened over a 10-year period will have a false positive mammogram. This occurs when the call-back for additional views and possible procedures ends up being non-cancerous. While around 12% of 2-D screening mammograms are recalled for more work-up, only 4.4% of those recalls, or 0.5% overall, conclude with a cancer diagnosis.³ Women deserve to know ALL the facts and be championed for making their own decisions.”

“The QTI team is very proud every time we ship a scanner to another location in the U.S. and doctors such as Dr. Karney get to offer our breast imaging technology to women. Our commitment is to keep doing this until all women will have a choice,” said Dr. Raluca Dinu, Chief Executive Officer at QTI.

About QT Imaging Holding, Inc.

QT Imaging Holdings, Inc. is a public (NASDAQ: QTI) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the company’s website at www.qtimaging.com.

Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc.

About Vitality Renewal Functional Medicine

Learn more at Home | Vitality Renewal | Dr. Yvonne Karney.

References

(1)	https://www.mdanderson.org/cancerwise/What-is-invasive-lobular-carcinoma-8-insights-on-lobular-breast-cancer.h00-159539745.html
(2)	https://www.cancer.gov/types/breast/breast-changes/dense-breasts
(3)	Ho TH, Bissell MCS, Kerlikowske K, et al. Cumulative Probability of False-Positive Results After 10 Years of Screening With Digital Breast Tomosynthesis vs Digital Mammography. JAMA Netw Open. 2022;5(3):e222440.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as “will,” and “expect,” or the negative thereof or comparable terminology, and include (without limitation) statements regarding the shipment by QT Imaging Holdings to the Vitality Renewal Functional Medicine of a Breast Acoustic CT™ Scanner, plans for QT Imaging Holdings, new product development and introduction, and product sales growth and projected revenues. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: research results from the use of the Breast Acoustic CT™ Scanner, the ability of QT Imaging Holdings to sell and deploy the Breast Acoustic CT™ Scanner, the ability to extend product offerings into new areas or products, the ability to commercialize technology, unexpected occurrences that deter the full documentation and “bring to market” plan for products, trends and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to attract and retain qualified personnel and the ability to move product sales to production levels. Additional factors that could cause actual results to differ are discussed under the heading “Risk Factors” and in other sections of QT Imaging Holding’s (and its predecessor, GigCapital5, Inc.) filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging Holdings as of the date hereof, and QT Imaging Holdings assumes no obligation to update any forward-looking statement.